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Summary Urinary tract infections (UTIs), which are among the most prevalent bacterial infec-
tions worldwide, are mainly attributed to uropathogenic Escherichia coli (UPEC). Because of
frequent antibiotic treatment, antimicrobial resistance constitutes an increasing therapeutic
problem. Antagonists of the mannose-specific bacterial lectin FimH, a key protein mediating
the adhesion of UPEC to human bladder cells, would offer an alternative anti-adhesive treat-
ment strategy. In general, FimH antagonists consist of a mannose moiety and a wide range of
lipophilic aglycones. Modifications of the mannose core led to a distinct drop in affinity. A visual
inspection of the crystal structure of FimH revealed a previously unexplored cavity surrounded
by Ile13, Phe142 and Asp140, which could be reached by functional groups in the equatorial
2-position of the mannose. Here, we describe the synthesis of 2-C-branched mannosides and
evaluation of their pharmacodynamic properties. ITC experiments with the selected antagonistsPlease cite this article in press as: Schönemann, W., et al
antagonists—–Synthesis and biological evaluation. Perspect. Sci
revealed a drastic enthalpy loss for all 2-C-branched antagonists, which, however, is partially
compensated by an entropy gain. This supports the hypothesis that the target cavity is too small
to accommodate 2-C-substituents.
© 2016 Published by Elsevier G
(http://creativecommons.org/li
Abbreviations: UPEC, uropathogenic Escherichia coli; UTI, urinary
maximal inhibitory concentration; ITC, isothermal titration calorimetry;
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Figure 1 The crystal structure of FimHLD co-crystallized with
n-heptyl  -D-mannopyranoside (1, PDB ID: 4BUQ) (Fiege et al.,
2015). A mainly hydrophobic cavity formed by Ile13, Phe142 and
Asp140 is located next to the entrance of the mannose binding
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ntroduction
rinary tract infections (UTIs) are among the most prevalent
acterial infections affecting millions of people (Foxman
t al., 2000). They are mainly associated with uropathogenic
scherichia coli (UPEC) (Roland, 2002). Currently, the
rst-line treatment involves antibiotics (Hooton et al.,
004; Fihn, 2003) which can induce resistance, especially
hen frequently applied (Sanchez et al., 2012). Therefore,
ovel and efficient non-antibiotic approaches are urgently
eeded.
In the first step of the infection cycle, UPEC attach to
rothelial cells of the host by means of the bacterial adhesin
alled FimH, which is located at the tip of the approximately
00 bacterial type 1 pili (Mulvey et al., 2000; Schilling et al.,
001). This allows UPEC to evade elimination from the host
rganism by the bulk flow of the urine. FimH is composed of
lectin domain (FimHLD) containing a carbohydrate recog-
ition domain (CRD) and a pilin domain (FimHPD) regulating
he switch between the high and low affinity states of the
RD (Le Trong et al., 2010).
More than thirty years ago, Firon et al. (1982, 1983, 1987)
eported on aryl  -D-mannosides abolishing FimH-mediated
ggregation of UPEC with mannan-containing yeast cells
Saccharomyces cerevisiae) in in vitro assays. Over the
ourse of the last few years, a range of highly potent mono-
alent antagonists consisting of a mannose moiety and a
ipophilic aglycone was reported (Bouckaert et al., 2005;
perling et al., 2006; Han et al., 2010; Klein et al., 2010;
usumano et al., 2011; Han et al., 2012; Pang et al., 2012;
iang et al., 2012; Schwardt et al., 2011; Kleeb et al., 2015;
rument et al., 2013; Jarvis et al., 2016; Chalopin et al.,
016). The various aglycones provide hydrophobic contacts
r — stacking interactions to amino acids forming the
ntrance to the mannose binding pocket. This entrance
alled ‘tyrosine gate’ is composed of two tyrosines and one
soleucine. However, the pharmacokinetic properties, e.g.,
olubility and/or permeability, of most of the reported FimH
ntagonists are not suitable for an oral application. For
hysicochemical and pharmacokinetic reasons, the numer-
us reported multivalent FimH antagonists (Lindhorst et al.,
998; Nagahori et al., 2002; Appeldoorn et al., 2005; Patel
nd Lindhorst, 2006; Touaibia et al., 2007; Durka et al.,
011; Bouckaert et al., 2013) are rather suited for the
herapy of E. coli induced colitis ulcerosa, a form of inflam-
atory bowel disease (Barnich et al., 2007; Carvalho et al.,
009).
When interacting with FimH, the mannose moiety estab-
ishes a perfect hydrogen bond network (Hung et al., 2002).
ince every hydroxyl group of mannose is part of this
etwork, the removal/replacement of individual various
ydroxyl groups or the replacement of the whole mannose
oiety by other hexoses (e.g., glucose, galactose, fruc-
ose) resulted in a significant loss of affinity (Bouckaert
t al., 2005; Han et al., 2010; Old, 1972; Fiege et al.,
015). Moreover, recently reported 1-C-branched mannose
erivatives bearing additional equatorial groups at the
nomeric carbon also showed reduced activity compared toPlease cite this article in press as: Schönemann, W., et al
antagonists—–Synthesis and biological evaluation. Perspect. Sci
ethyl  -D-mannoside (Gloe et al., 2015). In contrast, when
he anomeric oxygen was replaced by carbon or nitrogen,
y
e
i
pite and can be reached by equatorial substituents in the 2-
osition of the mannose moiety.
anomolar affinity could still be reached (Schwardt et al.,
011; Brument et al., 2013; Chalopin et al., 2016).
A visual inspection of the crystal structure of FimHLD
o-crystallized with n-heptyl  -D-mannoside (1, PDB ID:
BUQ) (Fiege et al., 2015) revealed a previously unexplored
ydrophobic cavity formed by Ile13, Phe142 and Asp140,
hich is located close to the entrance to the mannose-
inding pocket (Fig. 1). By extending the 2-position of the
annose moiety with equatorial substituents (→derivatives
a—k, Fig. 2), an interaction with the hydrophobic cavity
hould become possible.
An adaption of the synthetic pathway of previously
eported 2-C-branched mannose derivatives, in which the
-position is modified at an early stage, lead to rather labori-
us approaches (Mitchell et al., 2007). We therefore planned
more convergent synthesis with a more flexible introduc-
ion of aglycones as well as equatorial substituents in the
-position.
esult and discussion
he synthetic route to 2-C-branched FimH antagonists fulfils
wo requirements: The facile introduction of various agly-
ones as well as various equatorial C-substituents in the
-C-position of the mannose moiety.
ynthesis
he synthesis of the 2-C-branched mannoside donor 5 is
epicted in Scheme 1. The 2-C-modified D-mannofuranose
was synthesized according to a literature procedure
tarting from commercially available D-mannose (Witczak
t al., 1984). Selective benzylation of the hydroxymethyl
roup using dibutyltin oxide (Malleron and David, 1998) fol-
owed by cleavage of the acetonides under acidic conditions., 2-C-Branched mannosides as a novel family of FimH
. (2016), http://dx.doi.org/10.1016/j.pisc.2016.10.002
ielded the 2-C-branched D-mannopyranose 4 (Waschke
t al., 2011). For its perbenzoylation with benzoyl chloride
n presence of a catalytic amount of 4-dimethylamino-
yridine (DMAP) in dry pyridine, elevated temperature
ARTICLE IN PRESS+ModelPISC-385; No. of Pages 9
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AFigure 2 Modifications of the mannose moiety of n-heptyl  -
(110—120 ◦C) had to be applied. Subsequently, the gly-
cosyl donor 5 was obtained by reaction with thiophenol
using BF3·Et2O as a promoter. To couple donor 5 with 1-
heptanol, different promoters were tested. Whereas with
NIS/TMSOTf or NIS/TfOH donor 5 was only partially con-
sumed after 24 h, it reacted within minutes in the presence
of commercially available p-nitrobenzenesulfenyl chloride
(p-NO2PhSCl) accompanied by silver triflate (AgOTf) (Crich
et al., 2008). Apart from the desired  -anomeric mannoside
6 (32%), the 2-OH deprotected  -anomer 7 (32%) and the 2-
OH deprotected  -anomer 8 (5%) were obtained as well. As
silver triflate-mediated glycosylation has been reported to
lead to partial transesterification affecting acetyl groups at
the 2-O-position, low stereoselectivity of the glycosylation
reaction was not unexpected (Ziegler et al., 1990; Nukada
et al., 1999; Murakami et al., 2007).
To functionalize the equatorial substituent in the 2-C-
position, 6 was debenzylated by catalytic hydrogenolysis to
afford the primary alcohol 9. However, attempts to mesy-
late its primary hydroxyl group failed. Since we attributed
the low reactivity of the hydroxyl group in 9 to steric hin-
drance, we switched to mannoside 7 with an unprotected
axial hydroxyl group in the 2-position.
Indeed, after hydrogenolysis of 7 (→11), we were able
to selectively mesylate the primary hydroxyl groups (→12).
However, displacement of the mesylate by fluoride using KF
in aprotic solvent in presence of crown ether at elevated
temperature afforded epoxide 14 instead of the desired flu-
oride 13. Under these reaction conditions, the strongly basic
fluoride is obviously deprotonating the axial hydroxyl group
followed by conversion of mesylate 12 into the epoxide 14
by an intramolecular SN2 mechanism. With an excess of LiCl,
epoxide 14 could be opened, leading to the chloride 15 in
41% yield. By acting as Lewis acid, the large excess of lithium
ions can facilitate opening of the epoxide. Apart from the
epoxide route, substituents can be introduced directly by
nucleophilic substitution (see Scheme 2). However, preva-Please cite this article in press as: Schönemann, W., et al
antagonists—–Synthesis and biological evaluation. Perspect. Sci
lence of one mechanism over the other may depend on the
nucleophile, i.e., its nucleophilicity and basicity as well as
temperature and concentration.
T
m
(
(nnopyranoside (1) by equatorial substituents in the 2-position.
The synthesis of a series of 2-C-branched FimH antago-
ists is depicted in Scheme 2. Debenzoylation of 6 under
emplén conditions (→2b) followed by Pd(OH)2-catalyzed
ydrogenolysis afforded test compound 2a. The configura-
ion at the anomeric carbon of deprotected derivative 2a
1JH,C = 169Hz) was unambiguously confirmed by the 13C—1H
oupling constant of the anomeric nuclei using undecoupled
3C NMR. In general, the coupling constant for the equato-
ial anomeric proton amounts to  ∼170Hz, while a value of
160Hz is indicative for an anomeric proton in axial orien-
ation (Bubb, 2003).
Uponmesylation of 11, chloride was introduced using LiCl
ollowed by deprotection of the intermediate with sodium
ethoxide to afford derivative 2d. Direct introduction of
hloride starting from mesylate was faster and gave a higher
ield than the already discussed opening of epoxide 14.
ince only traces of epoxide were observed by TLC control,
N2 reaction seems to be the prevailing mechanism in this
articular case. However, more basic nucleophiles may lead
o different results.
Using an identical synthetic approach, iodide 2c, cyanide
e and azide 2h were obtained with NaI, KCN and NaN3
s nucleophiles. Hydrogenation of iodide 2c, cyanide 2e
nd azide 2h in presence of Pd(OH)2 on carbon yielded
he methyl derivative 2f and amine derivatives 2g and
i, respectively. In addition, when 2h was hydrogenated
nd subsequently acylated with acetyl chloride or propionyl
hloride followed by deacetylation under Zemplén condi-
ions, amides 2j and 2k were obtained.
To evaluate the  -anomeric derivative as well in
he biological assay,  -mannoside 8 was debenzoylated
→16b, Scheme 3) followed by hydrogenolysis to yield 16a
1JH,C = 159Hz).
ffinity and thermodynamic profile., 2-C-Branched mannosides as a novel family of FimH
. (2016), http://dx.doi.org/10.1016/j.pisc.2016.10.002
he affinities of the 2-C-branched mannosides were deter-
ined in a cell-free competitive binding assay (Table 1)
Rabbani et al., 2010). The assay uses FimHLD-Th-His6
Th: thrombin cleavage site) as a target protein and a
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Scheme 1 (a) i. BnBr, Bu2SnO, TBAB, toluene, 120 ◦C  → 80 ◦C, 24 h; ii. Amberlyst-15 (H+), EtOH, H2O, 50 ◦C, 43 h, 90%; (b) i.
BzCl, DMAP, pyridine, 120 ◦C, 48 h; ii. PhSH, BF3·Et2O, DCM, 0 ◦C  → rt, 24 h, 42%; (c) 1-heptanol, p-NO2PhSCl, AgOTf, DCM, 4Å MS,
0 ◦C  → rt, 5 h, 32% for 6, 32% for 7, 5% for 8; (d) Pd(OH)2/C, H2, EtOH, AcOH, rt, 22 h, 86%; e) MsCl, TEA, DCM, 0 ◦C  → 65 ◦C, 7 h,
0 ◦C  →
L
b
C
o
t
a
a
a
p
r
i
r
F
o
(
f
F
m
a
v
i
u
m
T
e
e
o
n
t%; (f) Pd(OH)2/C, H2, EtOH, rt, 5 h, 93%; (g) MsCl, TEA, DCM, 0
iCl, DMF, 90 ◦C, 7 h, 41%.
iotinylated polyacrylamide glycopolymer as competitor.
onjugation of biotin with streptavidin-horseradish per-
xidase allows quantification of the bound polymer and
herefore the determination of the IC50. The activity of
ll antagonists was measured twice in duplicates. The
ntagonist n-heptyl  -D-mannopyranoside (1) was used as
reference compound and tested in parallel to ensure com-
arability. The affinities are referred to the activity of 1 as
IC50.
In addition to the competitive binding assay, ITC exper-
ments were performed with mannosides 1, 2a and 2f to
eveal a thermodynamic fingerprint of mannose-modified
imH antagonists (Table 2). ITC enables direct measurementPlease cite this article in press as: Schönemann, W., et al
antagonists—–Synthesis and biological evaluation. Perspect. Sci
f the dissociation constant (KD) and the change in enthalpy
H◦), which are further used to calculate the changes in
ree energy (G◦) and entropy (S◦) (Chen andWadsö, 1982;
reire et al., 1990).
r
s
Trt, 6 h, 86%; (h) KF, Kryptofix 2.2.2, DMSO, 100 ◦C, 2 h, 85%; i)
Unfortunately, all 2-C modifications proved to be detri-
ental to the affinity. Already the smallest substituent,
methyl group (→2f), resulted in a 2.8-fold higher IC50
alue. A comparable 4.1-fold drop in activity was observed
n ITC. This finding might be explained by an unexpected
nfavourable steric clash of Ile13 and/or Phe142 with the
ethyl group already too big to fit to the targeted cavity.
his hypothesis is supported by the considerably improved
ntropy term (−TS◦ −17.2 kJ/mol) compared to the ref-
rence 1, indicating an increased conformational flexibility
f the ligand. The resulting disruption of the hydrogen bond
etwork within the pocket is also reflected by a substan-
ial decline of enthalpy (H◦ +20.6 kJ/mol). A further., 2-C-Branched mannosides as a novel family of FimH
. (2016), http://dx.doi.org/10.1016/j.pisc.2016.10.002
eduction in affinity to the micromolar level for larger sub-
tituents, e.g., iodomethyl and chloromethyl (→2c and 2d,
able 1) is in full agreement with this argumentation.
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Scheme 2 (a) MeONa/MeOH, rt, 4 h, 85%; (b) Pd(OH)2/C, H2, EtOH, rt, 6 h, 75%; (c) i. MsCl, TEA, DCM, 0 ◦C  → rt, 1.5—6 h; ii. NaI,
LiCl, KCN or NaN3, DMF or DMSO, 70—100 ◦C, 3—64 h; iii. MeONa/MeOH, rt, 1—6 h, 39% for 2c, 38% for 2d, 11% for 2e, 73% for 2h;
(d) Pd(OH)2/C, H2, EtOH, TEA, rt, 44 h, 91%; (e) i. Pd(OH)2/C, H2, MeOH or EtOH, rt, 3—11 h; ii. 0.1% TFA or 0.01M HCl, H2O, MeOH,
Cl or
e
h
s
fi
e
t
s
s
p
c
(
t
A76% for 2g, 86% for 2i; (f) i. Pd(OH)2/C, H2, EtOH, rt, 7 h; ii. Ac
rt, 1.5—4 h, 20% for 2j, 38% for 2k.
Unexpectedly, the benzyloxymethyl group in 2b, despite
its bulkiness, only slightly reduced the activity compared to
the methyl substituent (→2f). Furthermore, 2b performed
better compared to the halogens 2c and 2d. This may result
from a smaller van der Waals radius of oxygen compared
to chloride or iodide. Moreover, a solvent exposed phenyl
ring can be involved in non-specific hydrophobic interactions
with the surface of the protein, attenuating the negative
effect of the size of the 2-C-branch.
The antagonists bearing hydrogen bond donating groups,
such as a hydroxyl group (→2a), an amine (→2i) or an
amide (→2j and 2k), were among the most active deriva-
tives. The hydroxymethyl group (→2a) led to roughly aPlease cite this article in press as: Schönemann, W., et al
antagonists—–Synthesis and biological evaluation. Perspect. Sci
5-fold drop in affinity in both, competitive binding assay
and ITC. Compared to the methyl group (→2f), this sub-
stituent was expected to disrupt the hydrogen bond network
even further due to its larger size and to cause additional
i
i
a
lCH3CH2COCl, pyridine, DCM, rt, 2.5—5.5 h; iii. MeONa/MeOH,
nthalpy costs due to a desolvation penalty related to the
ydroxyl group. However, the enthalpy loss in this case was
maller (H◦2a—2f = 6.1 kJ/mol) implying additional bene-
cial interactions formed by 2a. As a consequence, the
ntropy gain was limited (−TS◦ −10.4 kJ/mol) compared
o 2f. However, this beneficial effect was almost compen-
ated by a loss in entropy. Furthermore, the structurally
imilar aminomethyl derivative 2i was the most active com-
ound within the series with only 2.1-fold lower affinity
ompared to reference 1. Presumably, the hydroxymethyl
→2a) and aminomethyl (→2i) groups are involved in elec-
rostatic interactions with a hydrogen bond acceptor, i.e.,
sp140 or the backbone amide of Ile13. The improved affin-., 2-C-Branched mannosides as a novel family of FimH
. (2016), http://dx.doi.org/10.1016/j.pisc.2016.10.002
ty of 2i may result from the fact that the ammonium group
n 2i can form a slightly stronger interaction (Lopes Jesus
nd Redinha, 2011). Finally, when we incorporated a longer
inker between the nitrogen and the sugar moiety (→2g)
Please cite this article in press as: Schönemann, W., et al., 2-C-Branched mannosides as a novel family of FimH
antagonists—–Synthesis and biological evaluation. Perspect. Sci. (2016), http://dx.doi.org/10.1016/j.pisc.2016.10.002
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Scheme 3 (a) MeONa/MeOH, rt, 2 h, 68%; (b) Pd(OH)2/C, H2, EtOH, rt, 3 h, 93%.
Table 1 Affinity of FimH antagonists. The rIC50 values were calculated by dividing the IC50 of the compound of interest by the
IC50 of the reference compound n-heptyl  -D-mannopyranoside (1). rIC50 values below 1.0 are obtained for antagonists more
active than reference compound 1, whereas rIC50 above 1.0 are obtained for antagonists less active than reference compound
1.
Entry Compound R IC50 [nM] rIC50
1 1 48.9—65.2 1
2 2a OH 311.0 4.9
3 2b 340.9 5.4
4 2c l >2000 38.9
5 2d Cl >2000 304
6 2e CN 522.3 9.7
7 2f H 181.2 2.8
8 2g CH2NH2·HCl >2000 37.1
9 2h N3 437.0 6.9
10 2i NH2·CF3COOH 135.0 2.1
11 2j 182.5 3.4
12 2k 295.2 5.5
13 16a OH 446.4 7.0
14 16b 4400 69.4
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Table 2 Thermodynamic profile of FimH antagonists in binding to FimHLD-Th-His6 at 25 ◦C and pH 7.4.
Entry Compound R KD [nM]  G◦ [kJ/mol]  H◦ [kJ/mol]  −TS◦ [kJ/mol]
1 1 28.9  −43.0  −50.3 7.3
2 2f H 118.6  −39.5  −29.7  −9.9
−
h
d
d
t
A
F
F
A
S
c
h
R
A
B
B
B3 2a OH 154.0  
the affinity was lowered to the micromolar level. Similarly
to the aminomethyl derivative 2i, the amide 2j had one of
the best affinities in the series. However, elongation of the
aliphatic chain attached to the amide (→2k) again resulted
in reduction of potency.
Quite surprisingly, the  -anomeric derivative 16a
(Table 1, entry 13) performed only slightly worse than its  -
anomeric analogue 2a. However, when a benzyloxymethyl
group was introduced (→16b, entry 14) the affinity was
almost 13-fold lower than for its  -anomeric counterpart
2b, according to docking studies (data not shown) due to a
steric clash with Ile13.
Conclusions
A new family of mannose-based FimH antagonists equipped
with equatorial substituents at the 2-position of the sugar
moiety was designed and synthesized to target a cavity
located close to the entrance of FimH-CRD. Only when the
axial 2-hydroxyl group was unprotected (→11), the other-
wise unsuccessful substitution at the equatorial 2-position
of the mannose moiety could be performed, leading to the
test compounds 2c—k. In one case, the intermediate epox-
ide 14 could be isolated, indicating two possible reaction
pathways; one via direct SN2-substitution and one via the
epoxide 14. The resulting epoxide intermediate could be
opened, however, affording only a moderate yield.
The activities of the 2-C-branched FimH antagonists
were evaluated in a cell-free competitive binding assay
and compared to the reference compound n-heptyl  -D-
mannopyranoside (1). None of the modifications proved
to be advantageous for binding to FimH-CRD. The loss
of affinity is probably related to steric hindrance as it
was already observed upon introduction of the smallest
substituent, a methyl group (→2f). With hydrogen bond
donating substituents (→2a, 2i—k), affinity could be par-
tially regained. Unexpectedly, the  -anomer 16a performed
only slightly worse than its  -anomeric counterpart 2a.
However, as already experienced in the  -series, a larger
benzyloxymethyl substituent (→16b) severely compromised
affinity.Please cite this article in press as: Schönemann, W., et al
antagonists—–Synthesis and biological evaluation. Perspect. Sci
Finally, ITC experiments with the selected antago-
nists 1, 2a and 2f revealed a drastic enthalpy loss for
the 2-C-branched antagonists, which, however, is par-
tially compensated by an entropy gain. This supports the
B38.9  −35.8  −3.1
ypothesis that the target cavity is too small to accommo-
ate 2-C-substituents. However, with larger, hydrogen bond
onating substituents the enthalpy loss could be substan-
ially reduced.
cknowledgement
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